Atlantic Edge Private Wealth Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.2K Hold
275
﹤0.01% 389
2026
Q1
$10.1K Sell
275
-50
-15% -$2.37K ﹤0.01% 386
2025
Q4
$16.5K Buy
325
+50
+18% +$2.56K ﹤0.01% 328
2025
Q3
$15.3K Sell
275
-200
-42% -$11.7K ﹤0.01% 333
2025
Q2
$32.8K Hold
475
0.01% 241
2025
Q1
$33K Buy
475
+150
+46% +$12.4K 0.01% 230
2024
Q4
$28K Hold
325
0.01% 240
2024
Q3
$38.7K Hold
325
0.01% 220
2024
Q2
$46.4K Buy
325
+125
+63% +$16.6K 0.02% 200
2024
Q1
$25.7K Hold
200
0.01% 234
2023
Q4
$20.7K Buy
+200
New +$19.8K 0.01% 235

Other funds holding NVO

Atlantic Edge Private Wealth Management's NVO Position: Q2 2026 in Review

Atlantic Edge Private Wealth Management held its Novo Nordisk (NVO) position steady in Q2 2026 at 275 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #389.

Atlantic Edge Private Wealth Management first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $46.4K in Q2 2024. 549 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Atlantic Edge Private Wealth Management held 275 shares of Novo Nordisk worth $13.2K as of Q2 2026.
  • Atlantic Edge Private Wealth Management left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up ﹤0.01% of Atlantic Edge Private Wealth Management's portfolio in Q2 2026, its #389 holding.
  • Atlantic Edge Private Wealth Management first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
  • Atlantic Edge Private Wealth Management's Novo Nordisk position peaked at $46.4K in Q2 2024.
  • 549 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Atlantic Edge Private Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.